We were retained by the licensor of technology related to the testing and detection of DNA of the Human Papillomavirus.  We reviewed the books and records of the licensee for compliance with the license agreement and determined the licensee understated its royalty payment obligations by greater than 50%, failed to use the proper currency conversion rates and improperly understated sales by utilizing disallowed deductions. Our findings resulted in the renegotiation of the license agreement to include a more comprehensive and efficient royalty reporting methodology.